SAN DIEGO, July 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) will Webcast its Quarterly Update Conference Call for
the second quarter of 2008 on Monday, July 21, 2008 at 5:00 p.m. ET/2:00
p.m. PT. Daniel M. Bradbury, Amylin's President and Chief Executive
Officer, will lead the call. On the same date post-market, Amylin will
release financial results for the second quarter of 2008.
The call will be Webcast live through Amylin's corporate Web site and a
recording will be made available following the close of the call. To access
the Webcast, please log on to http://www.amylin.com approximately fifteen
minutes prior to the call to register, download and install any necessary
audio software. For those without access to the Internet, the live call may
be accessed by phone by calling (866) 244-4530 (U.S./Canada) or (703)
639-1173 (international), Conference ID# 1262019. A replay of the call will
also be available by phone beginning approximately two hours after the
close of the call and can be accessed at (888) 266-2081 (U.S./Canada) or
(703) 925-2533 (international), Conference ID# 1262019.
About Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed
to improving lives through the discovery, development and commercialization
of innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
located in San Diego, California with over 2,000 employees nationwide.
Further information on Amylin Pharmaceuticals is available at
http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
 back to top
Related links:
http://www.amylin.com
CONTACT:
Michael York, Senior Director, Investor
Relations of Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext.
8602
|
